Highlights Newsletter 3 This newsletter presents you the following key sessions: Watch the video interview with Prof. Dr. V. Cocquyt on the BELIS study: safety and tolerability of at home administration of trastuzumab (Herceptin®) subcutaneous for the treatment of patients with HER2-positive early breast cancer Analysis of cardiac safety of pertuzumab combined with trastuzumab and standard chemotherapy in patients with HER2-positive breast cancer revealed no new safety signals A new effective method to avoid sentinel node biopsy in patients with a preoperative diagnosis of ductal carcinoma in situ Overall survival data BOLERO-1: benefit everolimus in HR-negative patients Chemotherapy does not boost ageing progression in elderly breast cancer patients No elevated cardiac biomarkers after neoadjuvant anti-HER2 therapy